United Therapeutics (UTHR) CEO A Sells $5.2M of Stock
CEO Martine Rothblatt sold 9,500 shares valued at $5.2 million in a planned transaction ahead of earnings.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rothblatt Martine A, Chairperson & CEO at United Therapeutics Corporation ($UTHR), sold 9,500 shares at an average price of $550.70, worth about $5.23 million, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $UTHR is down 3.1% to date (from the $550.10 close on Oct 12, 2026).
UTHR
United Therapeutics Corporation
Key Points
- Martine Rothblatt sold 9,500 shares of United Therapeutics for about $5.2 million on October 12, 2026.
- The stock recently traded around $541.98, which is above its 50-day moving average by 5.3%.
- United Therapeutics has a market cap of about $22.9 billion and a P/E ratio of 19.1.
Get $UTHR trade alerts by text
We text you when insiders, Congress or big funds trade $UTHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares on October 12, 2026, in a planned transaction valued at approximately $5.2 million. This sale follows Rothblatt's earlier purchase of the same number of shares at a price of $135.42 on June 26, 2026.
Inside Rothblatt's Trade
Rothblatt's recent sale was executed at a price of $550.70 per share. This planned transaction comes as the company prepares for its upcoming earnings report on October 28, 2026. Rothblatt's sale adds to a series of trades, as she had previously bought shares just a few months earlier, reflecting her active management of her holdings in the company.
Other Institutional Activity in United Therapeutics
In the latest reporting period, several other institutional investors have adjusted their positions in United Therapeutics. Blackrock Inc. reduced its holdings by 105,297 shares, bringing its total to 5,294,529 shares worth about $2.8 billion. Avoro Capital Advisors LLC increased its stake by 147,804 shares, now holding 2,777,777 shares valued at approximately $1.5 billion. Meanwhile, State Street Corporation added 54,030 shares, resulting in a total of 1,898,064 shares worth about $1.0 billion.
United Therapeutics Corporation Stock Up 0.1%
The stock of United Therapeutics recently traded around $541.98, which is above its 50-day moving average by 5.3%, indicating a positive trend. However, it is 11.1% below its 52-week high of $609.35, suggesting that there may still be room for growth. The current price is also below the average analyst target of $656.93 by about 17.5%.
Recent Earnings
United Therapeutics reported trailing twelve-month revenue of approximately $3.15 billion, with a net margin of 41.6%. The company has faced a slight revenue decline of 1.9% year-over-year, which could be a point of focus in the upcoming earnings report.
Insider Buying and Selling at United Therapeutics Corporation
In addition to Rothblatt's recent sale, she had previously purchased 9,500 shares at $135.42 on June 26, 2026, and again on June 29, 2026, for the same number of shares. These transactions reflect her confidence in the company's performance over time.
Analysts Set New Price Targets
On October 8, 2026, RBC Capital maintained an "Outperform" rating for United Therapeutics, raising its price target to $708.00 from $677.00. Meanwhile, Goldman Sachs initiated a "Sell" rating with a target of $321.00 on September 24, 2026. The consensus among analysts is a "Buy" rating based on 14 opinions, with a mean price target of $656.93.
About United Therapeutics
United Therapeutics Corporation develops and commercializes products to meet the medical needs of patients with chronic and life-threatening diseases. The company, headquartered in Silver Spring, MD, operates in the healthcare sector, particularly within the drug manufacturing industry.
Bottom Line
Investors will be watching for the upcoming earnings report on October 28, 2026, as well as any further insider trades. Rothblatt's planned sale may signal her strategic approach to managing her position ahead of this financial update.
Related Filing Alerts
Source: Rothblatt Martine A's Form 4 filing on $UTHR (Oct 12, 2026). Find the original filing: UTHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts